More Durable Protection

The TechImmune approach targets conserved viral genes as components of a superior next-generation SARS-CoV-2 vaccine, with strong potential to provide broader and more durable protection against variants of concern compared to the standard of care spike-only vaccines.

EST. 2021

TechImmune is advancing the development of a next-generation, broad-spectrum COVID vaccine, designed to obviate the necessity for frequent updating and recurrent boosting that characterize existing vaccines. Our innovative strategy targets multiple antigens to elicit a comprehensive immune response, involving both antibody and T cell activation, in contrast to conventional vaccines that utilize the Spike protein to induce neutralizing antibodies. TechImmune's Coronavirus vaccine encompasses a more advanced approach to enhance long-lasting immunity and disrupt the current booster paradigm.

The TechImmune Difference - Read More

Mission

Develop a pre-emptive next-generation “2.0” pan-coronavirus vaccine to protect the public and economic health of individuals and societies globally by providing long-lasting broad protection from all current and future variants. License the vaccine following early-stage clinical testing.

Contact Us

Vision

TechImmune is developing a pre-emptive next-generation “2.0” pan-coronavirus vaccine that confers potent and broad immunity to provide a long-term solution to current and future outbreaks of CoV. This vaccine could be implemented as a booster of choice and to prevent potential future pandemics.

OUR LEADERSHIP TEAM

Gavin Herbert

EXECUTIVE CHAIRMAN

Mr. Herbert has spent over 50 years in the pharmaceutical industry. He is the co-founder of Allergan Inc., CEO and Chairman of the Board for 30 years. Mr. Herbert served as Executive Vice President of SmithKline Beckman. He received his B.S. in Business, from the University of Southern California.

Jeffrey Ulmer, PhD

CEO and Board Member

Dr. Ulmer has >30 years of experience in Vaccines R&D and most recently served as the Global Head of External Research at Novartis and the Head of Preclinical R&D US at GSK Vaccines. Specialties: Biochemistry, Immunology and Cell Biology. Dr. Ulmer received his PhD from McGill University and post-doctoral fellowship at Yale University School of Medicine.

Richard Haugen

Rick Haugen
CFO and Board Member

Mr. Haugen was the CEO and President of a public firm, Amylin Pharmaceuticals. He spent 17 years with Allergan Inc. of Irvine culminating that career as Chief Operating Officer of the billion plus global company. He received his B.S. and MBA from the University of Southern California.

Lbachir BenMohamed, PhD

LBachir BenMohamed
Vice President and Board Member

In 2002, Dr. BenMohamed founded the Cellular & Molecular Immunology Laboratory at UC Irvine. He is the lead investigator for Techlmmune. He is a recipient of several United States National Institute of Health (NIH) grants. He completed his PhD in Immunology at the Pasteur Institute, Paris, France.

Dan Gil, PhD

Daniel Gil Headshot
COO and Board Member

Dr. Gil has had a 30+year career in Pharmaceutical R&D as VP of Research at Allergan. Dr. Gil has an undergraduate degree in Biology from Harvard University and a PhD in Pharmacology from University of Pennsylvania.

Dr. Trevor Jones CBE, PhD, DsC

Board Member

Former Head of Research for Burroughs Welcome, UK for over 20 years. Served as Head of British Pharmaceutical Association. He has been an advisor to the UK Government and G7 pandemic preparedness “100” days initiatives
to develop diagnostics, vaccines, and therapeutics for global use.

James Cavanaugh, PhD

James Cavanaugh PhD
Board Member

Dr. Cavanaugh is a Managing Director and Senior Advisor to HealthCare Venture LLC, a private equity and venture capital firm specializing in early stage biotechnology investments. He was previously President of SmithKline & French. He also served as President of Allergan International. Dr. Cavanaugh received his B.S. from Farleigh Dickinson University, M.A. and his Ph.D. from University of Iowa.

Gregory M. Glenn M.D.

Board Member

The former Novavax R&D President has over 30 years of experience in vaccine development, including a fellowship at WRAIR and founding IOMAI for skin-based vaccine delivery, later acquired by Intercell (now Valneva). Joining Novavax in 2010, he specialized in adjuvant and delivery systems for RSV, Influenza, and COVID-19, co-authoring over 140 publications and contributing to the licensure of MatrixM/R21 (Malaria) and Nuvaxovid (COVID-19) vaccines.

Feb 2023

Current Situation and Future Needs

Since early 2020, a deadly pandemic caused by a new Coronavirus (SARS-CoV-2) has threatened public health, world economies, and quality of life on a global scale. As of March 2024, the COVID-19 outbreak has resulted in 775 million confirmed cases and >7 million deaths worldwide ().

Unlike the previous CoV outbreaks, which were successfully managed using public health measures, containment of SARS-CoV-2 will require a concerted effort involving vaccines and therapeutics, along with public health measures. While the successes with first generation of CoV vaccines have been remarkable, it is becoming clear that a better and long-term solution to end the current pandemic and prevent future outbreaks is desperately needed.

During the COVID-19 outbreak, mutations and deletions in the Spike protein gene have produced a succession of fast spreading and pathogenic SARS-CoV-2 variants of concern (VOCs) with the potential to escape vaccine-induced immunity. Despite the deployment of >13 billion doses of CoV vaccine worldwide,  COVID-19 still accounts for 3 times as many deaths as influenza. These stark numbers emphasize the need for a superior, next-generation vaccine that induces broad-based, cross-reactive, and long-lasting immunity.

Recently, the Food & Drug Administration (FDA) announced a recommendation that  vaccines should be given on an annual basis, confirming the belief of the scientific community that COVID-19 with will be with us for a long time.

The Need

Vaccines were initially very effective at conferring protective immunity through the induction of neutralizing antibodies directed against spike protein. However, real-world data collected since deployment of the vaccines has demonstrated waning immunity over time and emergence of viral variants of concern (VOC) containing mutations in the spike protein with potential to escape vaccine-induced immunity. Hence, there is a pressing need to move beyond a narrow focus of immunity directed against a single viral antigen.

The Opportunity

In order to create a pre-emptive next-generation Coronavirus vaccine, effective against all coronavirus variants – future, current, and past – TechImmune is developing a broad-spectrum vaccine targeting spike plus other more conserved antigens to elicit both neutralizing antibodies and cross-strain T cell responses.

GRANTS and CONTRACTS

TechImmune, LLC has been awarded a business (SBIR) grant from the U.S. National Institute of Allergy and Infectious Diseases (NIH) to develop a Universal Vaccine Against Multiple Coronavirus Variants of Concern.

Additional grants are pending.

TechImmune has an exclusive license agreement that covers 6 patent applications. Future government grants are pending in the current year.

FUNDING STRATEGY

TechImmune continues to raise additional funding in the 1st half of 2024.

Email Us

TECHIMMUNE
INVESTOR INFORMATION

Richard Haugen, CFO

+1 (949) 374-1661

INVESTOR RELATIONS

Christine Dwight

+1 (949) 691-4350

5270 California Avenue, Suite 300

Irvine, CA. 92617

Join Our Mission!

Contact Us